Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 32Myelodysplastic Syndromes 25Recurrence 18Multiple Myeloma 17Lymphoma, Non-Hodgkin 14Lymphoma, B-Cell 14Lymphoma 14Leukemia, Lymphocytic, Chronic, B-Cell 13Ovarian Neoplasms 12Hematologic Neoplasms 12Pancreatic Neoplasms 10Melanoma 10Leukemia 9Hodgkin Disease 9Burkitt Lymphoma 9Stomach Neoplasms 8Myeloproliferative Disorders 8Lymphoma, Large B-Cell, Diffuse 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 7Leukemia, Biphenotypic, Acute 7Colorectal Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6Leukemia, Myelomonocytic, Juvenile 6Leukemia, Myelomonocytic, Chronic 6Breast Neoplasms 6

Interventions

thymoglobulin 1fludarabine 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Sickle Cell × fludarabine × 90 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡